AGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Agilon Health Inc (AGL) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is showing significant bearish trends in technical indicators, analysts have lowered price targets, and there are no recent positive news catalysts. While insider and hedge fund buying is a positive sign, the overall sentiment and financial performance do not justify immediate investment.
The stock is in a bearish trend with MACD negatively expanding, RSI indicating oversold conditions at 18.226, and moving averages showing a bearish alignment (SMA_200 > SMA_20 > SMA_5). The price is below key support levels, with S1 at 0.406 and S2 at 0.346, suggesting further downside risk.
Insiders and hedge funds are buying, with insider buying up 490.98% in the last month and hedge fund buying up 1326.49% in the last quarter. Financial performance shows improvement in net income and EPS YoY.
Analysts have lowered price targets significantly, with Citi reducing the target to 75c and Barclays reducing it to 50c. The stock missed Q4 earnings expectations, and the market sentiment is bearish with a 10.86% drop in regular trading. No recent news or congress trading data is available to support a positive outlook.
In Q4 2025, revenue increased by 3.09% YoY to $1.57 billion. Net income improved by 78.54% YoY but remains negative at -$188.88 million. EPS improved by 76.92% YoY to -0.46, and gross margin improved significantly but remains negative at -5.02%.
Analysts have a neutral to negative outlook. Citi lowered the price target to 75c from 85c, maintaining a Neutral rating. Barclays reduced the price target to 50c from $1 and maintains an Underweight rating. Despite a Q4 miss, the company guided 2026 above consensus.
